News

TSO3 CEO Presenting at Canaccord Growth Conference in Boston

Quebec City, August 11, 2011 – TSO3 Inc. (“TSO3”) (TSX: TOS) an innovator in sterilization technology for medical devices in healthcare settings, announced today that Mr. R.M. (Ric) Rumble, CEO of TSO3, will be giving a corporate presentation at 11:00 a.m (ET) today, at the Canaccord Genuity Annual Growth Conference.

Read more

News

TSO3 Announces Financial Results for Q2 2011

Quebec City, August 9, 2011 – TSO3 Inc. (“TSO3”) (TSX: TOS) an innovator in sterilization technology for medical devices in healthcare settings, posted its highest quarterly revenues in its second quarter of 2011. For the period ending June 30, 2011, the Company posted revenues of $703,000 from the sales of 3M™ Optreoz™ 125-Z Sterilizers, accessories, consumables and service contracts, as well as license revenues. This amount also includes sales of supplies and service contracts on first generation sterilizers (125L). These revenues compare to Q2 2010 revenues of $545,604, for the sale of 3M™ Optreoz™ Sterilizers, accessories, supplies and service contracts to 3M™ for training purposes. For the six-month period ended June 30, 2011, revenues amounted to $892,554 compared to $733,878 for the same period in 2010. The difference is explained by higher sales of private labelled 3M™ Optreoz Sterilizers and Accessories as a result of initial 3M™ commercial activity.

Read more

News

TSO3 Files for Commercial Clearance in the United States

Quebec City, June 30, 2011 – TSO3 Inc. (“TSO3”) (TSX: TOS), an innovator in sterilization technology for medical devices in healthcare settings, announced today that it has resubmitted documentation to the United States (U.S.) regulatory authorities for the company’s STERIZONE® 125L+ Sterilizer (3M™ Optreoz™ 125-Z). Such a filing is in support of obtaining clearance for the new generation sterilizer to be sold within the United States.

Read more

News

TSO3 and 3M Expand Agreement – Increase Field of Use and add OR Product in Development

Quebec City, May 19, 2011 – TSO3 Inc. (“TSO3”) (TSX: TOS), an innovator in sterilization technology for medical devices in healthcare settings is pleased to announce that the company and 3M™ Infection Prevention Division have amended their December 2009 Global Agreement to include a second product, which is currently in development and destined for use in the operating room (OR). In addition, the companies have agreed to explore the industrial and scientific markets to determine commercial opportunities for the current product (3M™ Optreoz 125-Z).

Read more